Quality improvers for eggs, fertilized eggs, or embryos
By blocking the signal transduction of CXCL5 and CXCR2, specific substances were used to improve the quality of oocytes, fertilized eggs, and embryos, addressing the problem of decreased preimplantation embryo quality due to aging, increasing pregnancy and birth rates, and predicting the aging of oocytes, fertilized eggs, and embryos.
Patent Information
- Application Number
- CN201780059256.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2016-09-26
- Filing Date
- 2017-09-26
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2037-09-26
AI Technical Summary
Current technologies have failed to effectively improve the decline in preimplantation embryo quality due to aging, leading to lower pregnancy rates and higher miscarriage rates. Furthermore, there are ethical and safety issues associated with the egg donation process.
By blocking the signal transduction of CXCL5 and CXCR2, substances such as anti-CXCL5 antibodies, anti-CXCR2 antibodies, or CXCR2 antagonists can be used to inhibit the interaction between CXCL5 and CXCR2, thereby improving the quality of oocytes, fertilized eggs, and embryos.
It improved pregnancy and birth rates, reduced miscarriage rates, and predicted the aging of oocytes, fertilized eggs, and embryos by the concentration of CXCL5 in serum or ovarian tissue, thus addressing the problem of declining quality due to aging.
Smart Images

Figure CN110022897B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a quality improver for oocytes, fertilized eggs, and / or embryos containing a substance that inhibits signal transduction from CXCL5. Background Technology
[0002] Generally, the cells that make up the human body repeatedly divide and proliferate as we grow, but during this process, cells are exposed to various stresses associated with aging, leading to accumulated damage. Possible causes include oxidative damage caused by the accumulation of reactive oxygen species and DNA damage caused by ultraviolet radiation. The result is decreased mitochondrial function, impaired intracellular metabolism, and ultimately, cancer and cell death. Thus, the decline in cell quality with age is a phenomenon common to all life-bearing organisms, with humans being a prime example. Currently, the decline in cell quality associated with aging is unavoidable, and extensive research is being conducted to delay, halt, or improve this decline.
[0003] In the field of reproductive medicine, the decline in pre-implantation embryo quality due to aging is a major concern. This decline in quality leads to lower pregnancy rates and higher miscarriage rates due to implantation difficulties. Observations of infertility rates across different age groups show that infertility is 6% before age 25, surges from age 30 onwards, and reaches as high as 64% at age 40. Furthermore, in Japan, 55% of in-vitro fertilization (IVF) cases involve patients over 38 years of age. The average pregnancy rate for younger patients is 26%, decreasing in older patients to only 6.3% for those over 38.
[0004] It is known that CXCL5 is a chemokine that helps neutrophils to chemotactically activate and participates in inflammatory responses (Patent Document 1).
[0005] Existing technical documents
[0006] Patent documents
[0007] Patent Document 1: Japanese Patent Publication No. 2005-527189 Summary of the Invention
[0008] The problem that the invention aims to solve
[0009] Previous attempts to improve the quality of pre-implantation embryos due to age-related decline have not yet yielded highly effective methods. As a result, pregnancy using the mother's own embryos has been abandoned in favor of receiving eggs from younger women and achieving pregnancy through in-vitro fertilization / embryo transfer.
[0010] In pregnancies conceived through egg donation, ethical issues have been raised because the woman's egg is fertilized with the husband's sperm, and the pre-implantation embryo is transferred to the uterus. Furthermore, since the fetus is not her own, there are concerns about increased maternal immune abnormalities and pregnancy complications. Moreover, the egg donor must undergo frequent injections for ovarian stimulation and egg retrieval, which are highly invasive procedures, raising safety concerns.
[0011] On the other hand, while attempts have been made to improve the quality of preimplantation embryos by ingesting supplements that may reduce oxidative stress and inflammatory damage, no scientifically proven highly effective supplements have yet been found. In other words, there is a need for a method to improve the decline in the quality of preimplantation embryos caused by factors such as aging.
[0012] In order to meet these needs, the objective of this invention is to provide a method for improving the quality of pre-implantation embryos that are reduced due to factors such as aging.
[0013] Solution for solving the problem
[0014] The inventors conducted in-depth research to address the aforementioned problems. As a result, they discovered that CXCL5, a chemokine, induces embryonic aging, and that by inhibiting signal transduction from CXCL5, the decline in pre-implantation embryo quality caused by aging and other factors can be improved. Based on these findings, the present invention was completed.
[0015] That is, the present invention relates to the following.
[0016] [1] A quality improver for oocytes, fertilized eggs and / or embryos, which contains a substance that inhibits signal transduction from CXCL5.
[0017] [2] According to the improver described in [1], the substance that blocks signal transduction from CXCL5 is a substance that blocks the interaction between CXCL5 and CXCR2.
[0018] [3] According to the improver described in [2], the substance that inhibits the interaction between CXCL5 and CXCR2 is an anti-CXCL5 antibody or a fragment thereof, an anti-CXCR2 antibody or a fragment thereof, or a CXCR2 antagonist.
[0019] [4] The improver according to any one of [1] to [3], wherein the quality of the oocyte, fertilized oocyte and / or embryo decreases with age.
[0020] [5] A culture medium for ovum, fertilized egg and / or embryo, containing any of the improvers described in [1] to [4].
[0021] [6] A method for predicting the aging of oocytes, fertilized eggs and / or embryos, wherein the concentration of CXCL5 in serum isolated from the subject is used as an indicator to determine whether there is aging of oocytes, fertilized eggs and / or embryos.
[0022] [7] A method for predicting the aging of oocytes, fertilized eggs and / or embryos, wherein the concentration of CXCL5 in ovarian tissue isolated from the subject is used as an indicator to determine whether there is aging of oocytes, fertilized eggs and / or embryos.
[0023] [8] A method for improving the quality of an egg, fertilized egg, or embryo, comprising the step of contacting the egg, fertilized egg, or embryo with a substance that inhibits signal transduction from CXCL5.
[0024] [9] A method for culturing an oocyte, fertilized egg, or embryo, comprising the step of culturing the oocyte, fertilized egg, or embryo in a culture medium containing a substance that inhibits signal transduction from CXCL5.
[0025] Invention Effects
[0026] According to the present invention, by blocking the signal transduction from CXCL5 via CXCR2, the quality of oocytes, fertilized eggs, or embryos that decline due to aging or other factors can be improved, thereby increasing pregnancy / birth rates in in vitro fertilization and embryo transfer. Furthermore, by using the concentration of CXCL5 in blood or ovarian tissue as a biomarker, the aging of oocytes, fertilized eggs, or embryos can be predicted. Attached Figure Description
[0027] Figure 1 This is a graph showing the results of analyzing the biological functions of genes whose expression fluctuates based on a comparison of gene expression in blastocysts from young infertile patients and older infertile patients.
[0028] Figure 2 This is a graph showing the blastocyst arrival rate of embryos obtained through CXCL5 neutralizing antibodies, CXCR2 antagonists, and their combined use.
[0029] Figure 3 This graph shows the results of embryo transfer using a combination of CXCL5 neutralizing antibody and CXCR2 antagonist. A represents the implantation rate of mice in each group. B represents the litter retrieval rate of mice in each group.
[0030] Figure 4These graphs represent the embryo transfer results of embryos obtained by separately adding CXCL5 neutralizing antibodies and CXCR2 antagonists. A shows the implantation rate in the CXCL5 neutralizing antibody group. B shows the farrowing rate in the CXCL5 neutralizing antibody group. C shows the implantation rate in the CXCR2 antagonist group. D shows the farrowing rate in the CXCR2 antagonist group.
[0031] Figure 5 This is a graph showing the blastocyst arrival rate of embryos obtained by adding CXCL5 to young mice.
[0032] Figure 6 This graph shows the results of embryo transfer in young mice after adding CXCL5. A represents the implantation rate of each group of mice. B represents the litter retrieval rate of each group of mice.
[0033] Figure 7 This graph shows the expression levels of aging markers in embryos obtained by adding CXCL5 to young mice. A represents the expression level of p21. B represents the expression level of p53. C represents the expression level of PAI-1. D represents the expression level of IL-6.
[0034] Figure 8 This graph shows the concentrations of CXCL5 in the serum and ovaries of aged and young mice. A represents the concentration in serum. B represents the concentration in the ovary. Detailed Implementation
[0035] (Quality improver)
[0036] One aspect of this invention relates to a quality improver for oocytes, fertilized eggs, and / or embryos (hereinafter, sometimes simply referred to as a "quality improver"), which contains a substance that inhibits signal transduction from CXCL5. That is, the invention is characterized by using a substance that inhibits signal transduction from CXCL5 for the purpose of improving the quality of oocytes, fertilized eggs, and / or embryos. It should be noted that "improvement of the quality of oocytes, fertilized eggs, and embryos" can also be referred to as "improvement of the fertility of oocytes, fertilized eggs, and embryos."
[0037] As described in the embodiments below, the inventors have determined that the concentration of CXCL5 in the ovary increases with age. Furthermore, they have discovered that CXCL5 induces aging in oocytes, fertilized eggs, and embryos, leading to a decrease in embryo quality. Moreover, they have found that by blocking the signal transduction of CXCL5 via CXCR2, a chemokine receptor, the quality of oocytes, fertilized eggs, or embryos that is reduced due to CXCL5 can be improved. Based on these insights, the present invention was completed.
[0038] That is, the quality improver for eggs, fertilized eggs, and / or embryos of the present invention is a substance that inhibits signal transduction from CXCL5. There are no particular limitations as long as it improves the quality of eggs, fertilized eggs, or embryos. For example, substances that inhibit the interaction between CXCL5 and CXCR2 can be listed.
[0039] Substances that inhibit the interaction between CXCL5 and CXCR2 include: anti-CXCL5 antibodies or fragments thereof, anti-CXCR2 antibodies or fragments thereof, or CXCR2 antagonists. One or more of these can be used.
[0040] Examples of the aforementioned anti-CXCL5 antibodies, anti-CXCR2 antibodies, or fragments thereof include, for example, antibodies (neutralizing antibodies) or fragments thereof that inhibit the interaction between CXCL5 and CXCR2 by binding to CXCL5 or CXCR2.
[0041] Well-known antibodies can be used as anti-CXCL5 and anti-CXCR2 antibodies. While not specifically limited, examples of anti-CXCL5 antibodies include: Anti-CXCL5 antibody (abcam, R and D systems, LifeSpan Biosciences, ThermoFisher SCIENTIFIC), etc. Similarly, examples of anti-CXCR2 antibodies include: Anti-CXCR2 antibody (abcam), Human CXCR2 / IL-8RB Mab (R and D systems), Mouse Monoclonal CXCR2 / IL-8RB Antibody (Novuss Biologicals), CXCR2 / IL8RB antibody (ThermoFisher SCIENTIFIC), etc.
[0042] Anti-CXCL5 antibodies can also be prepared using CXCL5 or fragments thereof as antigens and through conventional methods, and such antibodies can also be used in this invention.
[0043] Anti-CXCR2 antibodies can also be prepared using CXCR2 or fragments thereof as antigens and through conventional methods, and such antibodies can also be used in this invention.
[0044] The antibodies mentioned above can be either polyclonal or monoclonal. They can also be complete antibody molecules or antibody fragments that specifically bind to antigens, such as Fab (fragment of antigen binding), F(ab')2, Fab', Fv, scFv (single chain Fv), dsFv (disulfide stabilized Fv), and CDR (complementarity determining region). Human chimeric antibodies or humanized antibodies can also be used.
[0045] Examples of CXCR2 antagonists include substances that, by competitively binding to CXCR2 with CXCL5, hinder the interaction between CXCL5 and CXCR2, but do not themselves have the ability to activate CXCR2.
[0046] As a CXCR2 antagonist, well-known antagonists can be used. Although there are no particular limitations, examples include SB225002 (TOCRIS).
[0047] For antibodies and antagonists that inhibit the interaction between CXCL5 and CXCR2, it is preferable to inhibit the binding of CXCL5 and CXCR2 to 50% or less, 40% or less, 30% or less, 20% or less, 10% or less, or 1% or less, compared to the binding in the absence of antibodies and antagonists. The antibodies and antagonists used in this invention can use CXCL5 and CXCR2, and are selected by known methods using whether or not their binding is inhibited. By inhibiting the binding of CXCL5 and CXCR2, signal transduction from CXCL5 via CXCR2 is blocked, which can improve the quality of oocytes, fertilized eggs, or embryos that decline due to aging, etc. The antibodies and antagonists used in this invention can also use CXCL5 and CXCR2, and are selected by known methods using whether or not signal transduction from CXCL5 via CXCR2 is inhibited.
[0048] By contacting the quality-improving agent of the present invention with the oocyte, fertilized egg, and / or embryo, signal transduction from CXCL5 via CXCR2 is blocked, thereby improving the quality of the oocyte, fertilized egg, or embryo that is reduced due to CXCL5. Examples of methods for contacting the quality-improving agent of the present invention with the oocyte, fertilized egg, and / or embryo include: adding the quality-improving agent of the present invention to a culture medium and culturing the oocyte, fertilized egg, or embryo in the culture medium. It should be noted that the embryo quality improvement in the present invention includes: contacting the quality-improving agent of the present invention with the oocyte and / or fertilized egg to improve the quality of the oocyte and / or fertilized egg, thereby improving the quality of the embryo; and contacting the quality-improving agent of the present invention with the embryo to improve the quality of the embryo. Similarly, the fertilized egg quality improvement in the present invention includes: contacting the quality-improving agent of the present invention with the oocyte to improve the quality of the oocyte, thereby improving the quality of the fertilized egg; and contacting the quality-improving agent of the present invention with the fertilized egg to improve the quality of the fertilized egg.
[0049] The quality-improving effect of the present invention on oocytes, fertilized eggs, or embryos can be confirmed by the following method: in a commonly used in vitro culture system, the quality-improving agent group of the present invention, compared with the quality-improving agent-free group, shows improvement in any one or more of the evaluation items related to pregnancy / delivery, such as blastocyst arrival rate, implantation rate, litter (fetus) retrieval rate, and miscarriage rate.
[0050] The application of the oocyte, fertilized egg, or embryo quality improver of the present invention is not particularly limited to individuals whose oocyte, fertilized egg, or embryo quality has decreased due to aging or other factors, and who require improvement. Examples include individuals whose oocyte, fertilized egg, or embryo quality has decreased due to aging-related increases in CXCL5 secretion; and individuals whose pregnancy / birth rates have decreased due to such decreased oocyte, fertilized egg, or embryo quality. The target group is mammals. While not specifically limited to mammals, this includes humans and non-human animals such as pigs, cattle, bovids, horses, buffalo, and other animals with commercial value for meat and dairy production.
[0051] (culture medium)
[0052] One aspect of the present invention relates to a culture medium (hereinafter, sometimes simply referred to as "culture medium") for oocytes, fertilized eggs, and / or embryos, containing a quality improver for oocytes, fertilized eggs, and / or embryos, which contains a substance that inhibits signal transduction from CXCL5. The culture medium for oocytes, fertilized eggs, and / or embryos of the present invention is characterized by containing the quality improver for oocytes, fertilized eggs, and / or embryos of the present invention, which can be used during the culture of oocytes, fertilized eggs, or embryos to improve the quality of oocytes, fertilized eggs, or embryos that have decreased due to CXCL5 secretion / increased secretion associated with aging, etc.
[0053] If the culture medium of the present invention contains the quality improver of oocytes, fertilized eggs, and / or embryos of the present invention as an active ingredient, then other ingredients are not particularly limited. For example, the quality improver of oocytes, fertilized eggs, and / or embryos of the present invention can be added to a known culture medium of oocytes, fertilized eggs, or embryos to manufacture the culture medium of the present invention.
[0054] Culture media for oocytes, fertilized eggs, or embryos used in in vitro fertilization can be of different compositions depending on the stage of development. There are no particular limitations on culture media previously used for culturing oocytes, fertilized eggs, or embryos; the quality improver for oocytes, fertilized eggs, and / or embryos of the present invention can be added to manufacture the culture media of the present invention. It should be noted that the preferred approach is to add the quality improver of the present invention to the culture media used for culturing fertilized eggs and to the culture media used for culturing embryos from the morula stage to the blastocyst stage.
[0055] More specifically, as culture media for eggs, fertilized eggs, or embryos used in in vitro fertilization, the following can be used: a first culture medium for culturing embryos from the fertilization of sperm and egg and from the post-fertilization (pronuclear stage) to the 16-cell stage; and a second culture medium for culturing embryos from the morula stage to the blastocyst stage. The first and second culture media can be the same. The first culture medium can be used for sperm collection and egg collection. These culture media are commercially available, and commercially available culture media can also be used in the manufacture of the culture media of this invention. Although there are no particular limitations, in addition to culture media used for laboratory animals, other first culture media include Sydney IVF Fertilization medium (Cook Medical), Sydney IVF Cleavage medium (Cook Medical), Sequential Fert (ORIGIO), Sequential Cleav (ORIGIO), Universal IVF medium (ORIGIO), and G-IVF. TM (Vitrolife), G-1 TMV5 (Vitrolife), etc., can be used as a secondary culture medium. Besides culture media specifically for laboratory animals, other options include Sydney IVF Blastosistmedium (Cook Medical), Seaquential Blast (ORIGIO), Blastassist medium (ORIGIO), and G-2. TM v5 (Vitrolife), etc.
[0056] Alternatively, inorganic salts, sugars, amino acids, cell-protecting substances, antibiotics, physiologically active substances, etc., can be dissolved in ultrapure water or distilled water, and the prepared culture medium can be used to manufacture the culture medium of the present invention.
[0057] Regarding the content of the quality-improving agent for oocytes, fertilized eggs, and / or embryos of the present invention in the culture medium, the concentration in the culture medium, if it is an antibody or a fragment thereof, can typically be 0.01 to 100 μg / ml, preferably 0.1 to 10 μg / ml. If it is an antagonist, it can typically be 1 to 100 nM, preferably 10 to 30 nM. When the antibody or a fragment thereof is used in combination with an antagonist, the ratio can typically be 28.6:1 to 2857.1:1, preferably 28.6:1 to 1000:1 (mass ratio).
[0058] In addition to using the culture medium of the present invention, the culture of oocytes, fertilized eggs, or embryos can also be carried out according to known culture methods. Although the culture conditions are illustrated below as examples, they are not limited to these conditions and can be appropriately modified according to the application, desired effect, etc.
[0059] The incubation temperature can usually be above 37°C. The incubation gas phase can usually be set to 5% CO2 or 95% O2.
[0060] Regarding the culture time, if it is for the pre-culture of eggs used for in vitro fertilization, it can usually be 1 to 2 hours; if it is for fertilized eggs, it can usually be 5 to 72 hours; and if it is for embryos after the morula stage, it can usually be 72 to 144 hours.
[0061] The quality improver of the present invention can be brought into contact with oocytes, fertilized eggs, or embryos during at least one of the following periods: pre-culture of oocytes, culture of fertilized oocytes, and culture of embryos after the morula stage.
[0062] The quality improver of the present invention can also be brought into contact with oocytes, fertilized eggs, or embryos during multiple culture periods. The contact time between the quality improver of the present invention and oocytes, fertilized eggs, or embryos can be all or part of each period.
[0063] The culture medium for eggs, fertilized eggs, and / or embryos of the present invention is applicable to mammalian eggs, fertilized eggs, and embryos for which there is a need to improve the quality of eggs, fertilized eggs, or embryos that have decreased due to aging, etc., and to improve the reduced success rate of in vitro fertilization / microinsemination caused by the deterioration of egg, fertilized egg, or embryo quality, etc., and is not particularly limited thereto. While not particularly limited to mammals, this includes humans and non-human animals, such as pigs, cattle, bovids, horses, buffalo, etc.
[0064] (Methods for predicting aging)
[0065] One aspect of the present invention relates to a method for predicting the aging of oocytes, fertilized eggs, and / or embryos, which uses the concentration of CXCL5 in serum isolated from the subject as an indicator to determine whether aging of oocytes, fertilized eggs, and / or embryos is present. Another aspect of the present invention relates to a method for predicting the aging of oocytes, fertilized eggs, and / or embryos (hereinafter, sometimes simply referred to as "aging prediction method"), which uses the concentration of CXCL5 in ovarian tissue isolated from the subject as an indicator to determine whether aging of oocytes, fertilized eggs, and / or embryos is present.
[0066] As illustrated in the examples described later, it was determined that the concentration of CXCL5 in the ovary is correlated with the concentration of CXCL5 in the serum. Therefore, in addition to using the concentration of CXCL5 in the ovary as an indicator, the concentration of CXCL5 in the serum is also used as an indicator, thereby enabling the prediction of the concentration of CXCL5 in the ovary and whether oocytes, fertilized eggs, or embryos are induced to age by CXCL5.
[0067] In this invention, serum can be cited as blood used as a specimen. Serum can be appropriately obtained by processing blood taken from a subject according to conventional methods.
[0068] In this invention, the ovarian tissue used as a specimen can include: ovarian tissue itself, ovarian tissue preparations, and components derived from ovarian tissue (ovarian cells, follicular fluid, granulosa cells, etc.), which can be appropriately obtained by processing the ovarian tissue taken from the subject according to conventional methods.
[0069] The concentration of CXCL5 in ovarian tissue is not limited to the concentration of CXCL5 protein, but can refer to the concentration of substances related to CXCL5 expression, etc. Here, "expression" means the transcription of the CXCL5 gene or the translation of the transcription product of that gene.
[0070] While not particularly limited, methods for determining the concentration of CXCL5 in serum or ovarian tissue can include, for example, immunochemical methods, various chromatographic methods such as HPLC, etc. When the relevant substance is nucleic acid, PCR methods such as RT-PCR can be used to determine the CXCL5 concentration. From the viewpoint of simplicity, it is preferable to perform the determination using an immunochemical method that uses an antibody that recognizes CXCL5.
[0071] There are no particular limitations on the immunochemical methods used to determine the concentration of CXCL5 in serum or ovarian tissue, and well-known methods can be listed, such as enzyme immunoassay (EIA), latex agglutination, immunochromatography, radioimmunoassay (RIA), fluorescence immunoassay (FIA), luminescent immunoassay, spin immunoassay, turbidimetry (measuring turbidity associated with the formation of antigen-antibody complexes), enzyme sensor electrode methods (using antibody solid-phase membrane electrodes to detect potential changes caused by binding to antigens), immunoelectrophoresis, and Western blotting. From the viewpoint of simplicity, determination by EIA, latex agglutination, or immunochromatography is preferred.
[0072] EIA methods include competitive methods where the enzyme-labeled antigen competes with the antigen in the sample, and non-competitive methods where no competition occurs. From the perspective of ease of operation, the preferred method is the sandwich enzyme-linked immunosorbent assay (sandwich ELISA), which uses two antibodies and is a non-competitive method.
[0073] When using CXCL5 concentration in serum or ovarian tissue as an indicator, for example, the CXCL5 concentration in serum or ovarian tissue of a control group (e.g., healthy individuals, young individuals, etc.) of the same species as the subject can be set as a cutoff value, or this concentration can be used as a baseline for the cutoff value. The CXCL5 concentration in serum or ovarian tissue as a control, the value based on this concentration, and the cutoff value can be appropriately set based on conventional methods, depending on the specimen, desired effect, etc.
[0074] If the CXCL5 concentration in serum or ovarian tissue isolated from the subject is higher than the cutoff value or a pre-set cutoff value, it is determined that the oocyte, fertilized egg, or embryo has aged. If the CXCL5 concentration in serum or ovarian tissue isolated from the subject is the same as or lower than the cutoff value, it is determined that the oocyte, fertilized egg, or embryo has not aged. This allows for the prediction of aging. Furthermore, by comparing the CXCL5 concentration in serum or ovarian tissue isolated from the subject with the cutoff value, the degree of aging can be predicted.
[0075] The aging prediction method of this invention is applicable to mammals, without particular limitation. While not specifically limited, mammals include humans and non-human animals such as pigs, cattle, sheep, horses, and buffalo.
[0076] (Quality improvement methods and training methods)
[0077] Furthermore, the present invention includes a method for improving the quality of oocytes, fertilized eggs, or embryos, comprising a step of contacting the oocytes, fertilized eggs, or embryos with a substance that inhibits signal transduction from CXCL5. Additionally, the present invention includes a method for improving the quality of oocytes, fertilized eggs, or embryos and increasing pregnancy / delivery rates, comprising a step of contacting the oocytes, fertilized eggs, or embryos with a substance that inhibits signal transduction from CXCL5. For details regarding the contact method, please refer to the above-described items.
[0078] Furthermore, the present invention includes a method for culturing oocytes, fertilized eggs, or embryos, comprising the step of culturing oocytes, fertilized eggs, or embryos in a culture medium containing a substance that inhibits signal transduction from CXCL5. For culturing conditions, etc., please refer to the content of the above-described items.
[0079] Example
[0080] The present invention will be described in detail below with reference to specific embodiments, but the present invention is not limited to the following embodiments.
[0081] <Example 1>
[0082] For pre-implantation embryos, the gene expression profiles of young infertile patients were compared with those of infertile patients over 39 years of age, comprehensively analyzing genes showing differences in expression. Among these, genes secreted by age and expressed more frequently in older patients were identified as candidate factors associated with decreased embryo quality due to aging. Specifically, the experiments were conducted as follows.
[0083] Gene expression in blastocysts from young and older patients was compared using DNA microarray inclusion. The results showed that 3789 genes exhibited expression fluctuations with a 5-fold or greater difference in expression levels. Biological function analysis of these genes revealed that genes related to metabolism and cell cycle were affected with age. Figure 1 ).
[0084] Genes that are secreted by fluctuating gene expression and are expressed more in older patients were extracted. CXCL5, which showed 202.8 times higher expression levels in the blastocysts of older patients than in younger patients, was selected as the final candidate factor.
[0085] <Example 2>
[0086] Regarding the candidate factor CXCL5 obtained in Example 1, the study investigated whether adding a neutralizing antibody and a specific receptor antagonist for CXCL5 improved the quality of age-related embryos in an in vitro culture system of aged mouse embryos. Mature oocytes released from 42-week-old aged mice were recovered and in vitro fertilized. The resulting zygotes were cultured in vitro using a medium supplemented with the neutralizing antibody and specific receptor antagonist for the candidate factor. The blastocyst arrival rate was determined to verify embryonic developmental capacity. Furthermore, the resulting blastocyst embryos were transferred to pseudopregnant mice, and the implantation rate and litter size were examined to further evaluate embryo quality. Specifically, the experiments were conducted as follows.
[0087] (Laboratory animals)
[0088] Female ICR mice (CLEA, Tokyo, Japan) were used as experimental animals. Mice were housed in a light-dark environment at 22°C and 55% humidity, with 12-hour intervals between light and dark conditions. Each mouse was given 6g of MF control diet (Oriental yeast, Tokyo, Japan) daily. Water was provided on a free-flowing basis. Three-week-old mice were used as young mice, and 42-week-old mice were used as aged mice. Five mice were placed in each group.
[0089] The handling and feeding of all mice were in accordance with the standards of the laboratory animal facility at the University of Santa Maria Medical School.
[0090] (In vitro fertilization and embryo culture)
[0091] Erosive cycles in mice aged 3 weeks and 42 weeks were confirmed using vaginal smears. At the designated time during proestrus, 10 IU of gonadotropin (ASKA Pharmaceuticals, Tokyo, Japan) was administered intraperitoneally. Fifteen hours after administration, cumulus-oocyte complexes (COCs) were retrieved from the oviduct and pre-cultured in 100 μl TYH medium (LSI Medience, Tokyo, Japan) for 30 minutes. During this period, male ICR mice (10–12 weeks old) were generally anesthetized with somnopentyl (Kyoritsu Pharmaceuticals, Tokyo, Japan), and the epididymal tail was removed. A portion of the epididymal tail was cut open, and sperm were recovered by squeezing. The recovered sperm fragments were immersed in a 1.5 mL microtube containing 400 μl of TYH medium and incubated for 10 minutes in a CO2 incubator (37°C, 5% CO2, 95% air). The sperm fragments were then added to 100 μl of TYH medium containing COCs to achieve a final concentration of 2–3 × 10⁻⁶. 5The cells were cultured at 37°C, 5% CO2, and 95% air for 5–6 hours. Sperm were removed from the cultured oocytes in 30 μl KSOM medium (Merck Millipore, Darmstadt, Germany), and the number of two-cell stage embryos was calculated. Then, for young and old mouse controls, the cells were transferred to another 30 μl KSOM medium and cultured in a CO2 incubator for 4 days. For the drug-treated groups, the embryos were transferred to 30 μl KSOM medium supplemented with 0.1 μg / ml, 1 μg / ml, and 10 μg / ml CXCL5 neutralizing antibody (ab135203, abcam) at final concentrations of 0.1 μg / ml, 1 μg / ml, and 10 μg / ml; to 30 μl KSOM medium supplemented with 10 nM and 30 nM CXCR2 antagonist (2725, TOCRIS) at final concentrations of 10 nM and 30 nM; and to 30 μl KSOM medium supplemented with both CXCL5 neutralizing antibody and CXCR2 antagonist. All embryos were cultured in a CO2 incubator for 4 days. The blastocyst arrival rate was calculated as the number of blastocysts divided by the number of two-cell stage embryos.
[0092] Neutralizing antibodies against CXCL5 and antagonists of the specific receptor were added to fertilized eggs of aged mice at different concentrations. The results showed no significant difference in blastocyst arrival rate between the control and drug-treated groups. Figure 2 ).
[0093] (Embryo transfer and cesarean section)
[0094] Four days after culture, embryos that reached the blastocyst stage were transferred. Recipient mice were 6-10 week old female ICR mice, mated with vasectomized male ICR mice the day before oocyte retrieval, and individuals with a vaginal plug confirmed the following day. General anesthesia was administered with somnopentyl, and the uterus was exposed by incision in the back. The uterus was fixed with forceps, and a 30G injection needle (Dentronics, Tokyo, Japan) was used to create an opening in the fallopian tube junction. A glass capillary tube, which had attracted the blastocyst, was inserted, and the embryo was transferred into the uterus. After transfer, the uterus was carefully returned to the body, and the retroperitoneum and skin were sutured. During transfer, blastocysts from each group of mice were individually transferred to recipient mice. The day after oocyte retrieval was designated as day one, and cesarean sections were performed on day nineteen. Recipient mice were euthanized, and the uterus was removed and the fetus was retrieved. The implantation rate is calculated by dividing the number of implantation traces by the number of embryos transferred, and the litter survival rate is calculated by dividing the number of litters by the number of implantation traces.
[0095] The blastocysts of both the control and drug-treated groups were transplanted into pseudopregnant mice. The implantation rate was significantly improved in the neutralizing antibody + antagonist group (one-way ANOVA followed by Tukey-Kramer test, *P<0.05 compared to the control group). Figure 3 Significant differences were observed between the neutralizing antibody (10 μg / ml) + antagonist (10 nM) supplementation group and the aged control group. Farrowing success rate was significantly higher in the neutralizing antibody (10 μg / ml) + antagonist (10 nM) supplementation group. Figure 3 ).
[0096] Both the group receiving neutralizing antibody alone (10 μg / ml) and the group receiving antagonist alone (10 nM) showed a higher tendency for implantation rate and farrowing success rate. Figure 4 ).
[0097] <Example 3>
[0098] In addition, in an in vitro culture system of young mouse embryos, the effects of adding candidate factors on blastocyst arrival rate, implantation rate, and litter size were investigated using the same methods as in Example 2. Furthermore, the expression of p16, p21, p53, PAI-1, and IL-6, which are aging markers, in the embryos was measured to examine whether they induced cellular senescence. Specifically, the experiments were conducted as follows.
[0099] Based on the method described in Example 2, in vitro fertilization and embryo culture were performed on young mice. However, the control group was transplanted into 30 μl of KSOM medium, while the drug-treated group was transplanted into 30 μl of KSOM medium supplemented with CXCL5 (ab9803, abcam) at a final concentration of 1000 nM (95°C, 5 min) and CXCL5 at final concentrations of 100 nM, 300 nM, and 1000 nM, respectively, and cultured in a CO2 incubator for 4 days. Then, the blastocyst arrival rate was calculated.
[0100] Fertilized eggs from young mice were supplemented with CXCL5 and heat-denatured CXCL5 before culture. The results showed no significant difference in blastocyst arrival rate between the control group and the control group without CXCL5. Figure 5 ).
[0101] Based on the method described in Example 2, blastocysts from the control group and the drug-treated group were transferred into pseudopregnant mice. Implantation rate and litter retrieval rate were then calculated.
[0102] Blastocysts obtained by adding CXCL5 and those obtained by heat-denaturing CXCL5 were transplanted into pseudopregnant mice. The results showed that the implantation rate was reduced in the CXCL5-added group (one-way ANOVA followed by Tukey-Kramer test, *P<0.05 compared to the control group). Figure 6 A significant difference was observed between the CXCL5 1000 nM supplementation group and the control group without supplementation. For farrowing success rate, no significant difference was observed between the two groups (one-way ANOVA followed by Tukey-Kramer test, *P < 0.05). Figure 6 Furthermore, no significant differences were observed between the heat-denatured CXCL5-added group and the control group in terms of implantation rate and farrowing success rate.
[0103] Real-time RT-PCR was used to determine the expression levels of aging markers (p16, p21, p53, PAI-1, IL-6) in embryos supplemented with CXCL5 (n=30). No difference was observed in p16 expression, but significant increases were observed in p21, p53, PAI-1, and IL-6 (T-test, *P<0.05 compared to the control). Figure 7 ).
[0104] <Example 4>
[0105] The concentrations of candidate factors in serum and ovarian tissue of young and old mice were measured to evaluate their potential use as biomarkers for predicting embryonic aging. Specifically, the experiments were conducted as follows.
[0106] Prior to in vitro fertilization in Example 2, serum and ovarian tissues were collected from young and aged mice, respectively. The concentrations of CXCL5 in serum and ovaries were measured using ELISA. The concentrations of CXCL5 in the serum and ovaries of aged mice showed significantly higher values than those in young mice (T-test, *P<0.05 compared to the control). Figure 8 Furthermore, it is known that the concentration of CXCL5 in serum tends to correlate with the concentration of CXCL5 in the ovary, and the concentration of CXCL5 in the ovary can be predicted based on the concentration of CXCL5 in serum.
[0107] It was clarified that inhibition of CXCL5-CXCR2 signaling in aging embryos has the following effects: improving the quality of oocytes, fertilized eggs, and embryos that decline due to age, and increasing pregnancy / birth rates in in vitro fertilization and embryo transfer. Furthermore, it was shown that CXCL5 induces embryonic aging, and its serum concentration is useful as a marker of aging in oocytes, fertilized eggs, and embryos.
[0108] Industrial availability
[0109] This invention is applicable to pharmaceuticals, medical devices, research reagents, etc.
Claims
1. The use of an anti-CXCL5 antibody or a fragment of said anti-CXCL5 antibody that specifically binds to CXCL5, said use being for manufacturing a quality improvement agent for fertilized eggs and / or preimplantation embryos, said quality improvement agent being used to improve the quality reduction of fertilized eggs and / or preimplantation embryos due to aging.
2. The application according to claim 1, wherein, Improvers for reduced quality of fertilized eggs and / or preimplantation embryos are used in humans.
3. The application according to claim 1, wherein, Agents that improve the quality of fertilized eggs and / or preimplantation embryos are used to improve implantation rates or litter (offspring) fertilization rates.
4. An application of a CXCR2 antagonist, said application being for manufacturing a quality improvement agent for fertilized eggs and / or preimplantation embryos, said quality improvement agent being used to improve the quality reduction of fertilized eggs and / or preimplantation embryos due to aging, said CXCR2 antagonist being SB225002.
5. The application according to claim 4, wherein, Improvers for reduced quality of fertilized eggs and / or preimplantation embryos are used in humans.
6. The application according to claim 4, wherein, Agents that improve the quality of fertilized eggs and / or preimplantation embryos are used to improve implantation rates or litter (offspring) fertilization rates.
7. The use of an anti-CXCL5 antibody or a fragment of said anti-CXCL5 antibody that specifically binds to CXCL5 and a CXCR2 antagonist in combination, said use for manufacturing a quality improvement agent for reducing the quality of fertilized eggs and / or preimplantation embryos, said quality improvement agent for improving the quality reduction of fertilized eggs and / or preimplantation embryos due to aging, said CXCR2 antagonist being SB225002.
8. The application according to claim 7, wherein, Improvers for reduced quality of fertilized eggs and / or preimplantation embryos are used in humans.
9. The application according to claim 7, wherein, Agents that improve the quality of fertilized eggs and / or preimplantation embryos are used to improve implantation rates or litter (offspring) fertilization rates.
10. The use of an anti-CXCL5 antibody or a fragment of said anti-CXCL5 antibody that specifically binds to CXCL5, said use being for a culture medium used to manufacture fertilized eggs and / or preimplantation embryos, wherein, The culture medium is used to improve the quality of fertilized eggs and / or preimplantation embryos that are reduced due to aging.
11. An application of a CXCR2 antagonist, said application being for a culture medium used to produce fertilized eggs and / or preimplantation embryos, wherein, The culture medium is used to improve the quality of fertilized eggs and / or preimplantation embryos that are reduced due to aging, and the CXCR2 antagonist is SB225002.
12. The use of an anti-CXCL5 antibody or a fragment of said anti-CXCL5 antibody that specifically binds to CXCL5 in combination with a CXCR2 antagonist, said use being for a culture medium used to produce fertilized eggs and / or preimplantation embryos, wherein, The culture medium is used to improve the quality of fertilized eggs and / or preimplantation embryos that are reduced due to aging, and the CXCR2 antagonist is SB225002.
Citation Information
Patent Citations
Compositions and methods for detection and treatment of diseases and conditions associated with chemokine receptors
JP2005527189A
